Dr. Yang and Abid Ansari, Chief Financial Officer of OncoC4, will also participate in one-on-one meetings throughout the week.
Based in Rockville, Maryland, OncoC4 is a privately held, late clinical-stage biopharmaceutical company developing and discovering novel immunotherapeutics targeting CTLA-4 and CD24-Siglec checkpoints to overcome cancer resistance to immunotherapy. Built on fundamental research from its co-founders, OncoC4 has developed a rich pipeline of drug candidates spanning preclinical to pivotal stage programs. Its lead clinical candidate, BNT316/ONC-392, is a Phase 3, next generation anti-CTLA-4 antibody designed to allow CTLA-4 recycling and maintain its protective function against autoimmune diseases while enhancing anti-tumor activity. BNT316/ONC-392 is part of a strategic collaboration with BioNTech announced in March 2023. OncoC4’s CD24-Siglec program develops products that target the CD24-Siglec immune checkpoint, including AI-071, a Phase 2 ready broad-based Siglec agonist for immune-related adverse events and ONC-841, a potential first-in-class anti-Siglec 10 monoclonal antibody targeting innate and adaptive immunity in the tumor microenvironment. To address multiple types of cancers, OncoC4’s CD24 oncology platform targets a unique cancer-selective CD24 epitope used by nearly 70% of tumors to evade innate immune destruction and includes monoclonal antibody, bi-specific antibody, antibody-drug conjugate, and CAR T-cell therapy approaches.
To learn more, please visit www.oncoc4.com.